Transparency Market Research in its new report titled, “Fecal Microbiota Transplantation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026, ” provides key insights on the fecal microbiota transplantation market. The TMR report states that the market is expected to create significant opportunities during the forecast period i. e, 2018-2026 owing to the increased research and development expenditure, entry of new players into the market through alliances and collaborations, and improved safety and efficacy over current therapeutic options. However, regulatory hurdles and disappointing results of promising pipeline molecules may hamper the market during the forecast period, says the report discussing the market restraints.
The TMR report has segregated the global fecal microbiota transplantation market based on disease indication and geography. On the basis of disease indication, the global fecal microbiota transplantation market is split into clostridium difficile infections, Parkinson disease, obesity, diabetes mellitus, autism, and others.
Among these, the clostridium difficile infection segment is expected to hold significant market share during forecast period due to a strong clinical pipeline of molecules in the highest phase of development. For example, Seres Therapeutics’s SER-109 is currently in phase 3 and is expected to enter the market by 2020.
Moreover, rise in prevalence of clostridium difficile infections and high rate of reoccurrence (around 15% to 30%) are expected to boost the market during the forecast period. The fecal microbiota transplantation market is currently in the nascent stage as no therapy has yet been approved. Yet, the increasing funding on research and development may play a vital role in driving the market during the forecast period, says the report.
From a regional perspective, the global fecal microbiota transplantation market is segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Among these, North America is anticipated to be dominant, followed by Europe. Strong clinical pipeline, presence of key players, rise in incidence and prevalence of chronic diseases, well-established health care infrastructure, increased research and development expenditure, and high demand for advance treatments are anticipated to propel the fecal microbiota transplantation market in North America and Europe.
The market in Asia Pacific is expected to expand at a high CAGR during the forecast period. Its expansion is expected to be driven by India and China owing to a large patient base, increased incidence of chronic diseases, rise in awareness, increased government initiatives toward the development of fecal microbiota-based therapeutics, rise in disposable income, and developing health care infrastructure in these countries. The global fecal microbiota transplantation market in Latin America and Middle East & Africa is anticipated to expand during the forecast period, owing to increase in investments from market players in these regions.
The leading companies in the global fecal microbiota transplantation market are profiled in this report to give a better competitive analysis and these include Rebiotix Inc. , Finch Therapeutics, Seres Therapeutics, and Crestovo LLC.
Request a free brochure report here - http://bit.ly/2TATxiQ
Transparency Market Research (TMR) is a U. S. -based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453